HC Wainwright Issues Pessimistic Estimate for MNPR Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities researchers at HC Wainwright reduced their Q1 2026 EPS estimates for shares of Monopar Therapeutics in a research note issued on Monday, March 30th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.77) per share for the quarter, down from their previous forecast of ($0.55). The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ Q2 2026 earnings at ($0.82) EPS, Q3 2026 earnings at ($0.91) EPS, Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($3.53) EPS, FY2027 earnings at ($1.81) EPS, FY2028 earnings at ($0.54) EPS, FY2029 earnings at $1.79 EPS and FY2030 earnings at $4.38 EPS.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.10).

MNPR has been the subject of a number of other reports. Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, January 22nd. BTIG Research reissued a “buy” rating and set a $104.00 target price on shares of Monopar Therapeutics in a research report on Monday, February 23rd. Chardan Capital restated a “buy” rating and set a $100.00 target price on shares of Monopar Therapeutics in a research note on Monday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $107.00.

Monopar Therapeutics Price Performance

NASDAQ:MNPR opened at $55.39 on Wednesday. The firm has a market capitalization of $370.56 million, a PE ratio of -30.43 and a beta of 1.64. The business’s fifty day moving average price is $58.68 and its 200 day moving average price is $70.92. Monopar Therapeutics has a 12 month low of $26.06 and a 12 month high of $105.00.

Hedge Funds Weigh In On Monopar Therapeutics

Several large investors have recently bought and sold shares of MNPR. Janus Henderson Group PLC increased its position in shares of Monopar Therapeutics by 2.3% during the fourth quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company’s stock worth $85,908,000 after purchasing an additional 30,042 shares in the last quarter. RA Capital Management L.P. boosted its position in shares of Monopar Therapeutics by 30.5% in the 4th quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock valued at $43,569,000 after purchasing an additional 156,000 shares during the period. ADAR1 Capital Management LLC boosted its position in shares of Monopar Therapeutics by 79.9% in the 4th quarter. ADAR1 Capital Management LLC now owns 233,908 shares of the company’s stock valued at $15,274,000 after purchasing an additional 103,909 shares during the period. Wellington Management Group LLP purchased a new position in Monopar Therapeutics during the 3rd quarter worth approximately $18,904,000. Finally, Siren L.L.C. purchased a new position in Monopar Therapeutics during the 4th quarter worth approximately $13,863,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Key Headlines Impacting Monopar Therapeutics

Here are the key news stories impacting Monopar Therapeutics this week:

• Positive Sentiment: Chardan Capital reaffirmed a Buy rating on MNPR, providing a straightforward positive catalyst that can support demand from growth-oriented investors. Chardan Capital Reaffirms Buy Rating for Monopar Therapeutics (NASDAQ:MNPR)
• Positive Sentiment: HC Wainwright materially increased Monopar’s long-term earnings outlook — raising FY2029 to $1.79 (from about -$0.07) and projecting FY2030 at $4.38 — and improved FY2027 and FY2028 estimates (less negative). These changes signal the analyst sees meaningful longer‑term upside tied to successful clinical/program milestones.
• Neutral Sentiment: HC Wainwright published a full slate of updated forecasts through FY2030 (Q1–Q4 2026 and multi-year projections). Investors should treat these as model-driven scenarios that reflect both near-term risk and long-term optionality rather than confirmed outcomes.
• Negative Sentiment: HC Wainwright cut near-term 2026 estimates across the board: Q1 2026 EPS to ($0.77) from ($0.55), Q2 to ($0.82) from ($0.58), Q3 to ($0.91) from ($0.65), Q4 to ($1.02) from ($0.73), and lowered FY2026 to ($3.53) from ($2.52). These downward revisions highlight bigger near‑term cash burn/expense or pushed-out milestones and are a clear negative for short-term earnings expectations.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.